Evidence map›Paper›PMID 39479465›Full record

ReviewOpen medicine (Warsaw, Poland)2024

CBD's potential impact on Parkinson's disease: An updated overview.

El Ghachi Hafida, Soulimani Rachid, Gamrani Halima, Kissani Najib

Abstract readReview
In one paragraph

Review in Open medicine (Warsaw, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Plant-derived therapies in Parkinson's disease: a systematic review of clinical evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

El Ghachi HafidaNeurosciences, Pharmacology, and Environment Unit (NPEU), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh, Morocco.
Soulimani RachidLCOMS/Neurotoxicologie Alimentaire et Bioactivité, Université de Lorraine, 57000, Metz, France.
Gamrani HalimaNeurosciences, Pharmacology, and Environment Unit (NPEU), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh, Morocco.
Kissani NajibDepartment of Neurology, Faculty of Medicine and Pharmacy, University Hospital Mohamed VI, Medical Research Center, University Cadi Ayyad, 40000, Marrakesh, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Parkinson's disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients' quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often associated with severe side effects. This creates an urgent need for effective alternatives targeting both motor and non-motor symptoms. Objectives: Over the past decade, Methods: This review compiles data on both motor and non-motor symptoms of PD, integrating results from preclinical animal studies and available clinical trials. Results: Preclinical research has demonstrated promising results regarding CBD's potential benefits in PD; however, the total number of clinical trials is limited (with only seven studies to date), making it difficult to draw definitive conclusions on its efficacy. Conclusions: While preclinical findings suggest that CBD may have therapeutic potential in PD, the limited number of clinical trials highlights the need for further research. This review emphasizes the gaps that need to be addressed in future studies to fully understand CBD's role in treating both motor and non-motor symptoms of PD.

Indexed as

cannabidiolclinical trialsl-DOPA-induced dyskinesianon-motor symptomsParkinson’s disease

Identifiers

PMID39479465
PMCPMC11524397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.